JX594 + TG6006

**JX594 + TG6006** (also known as Pexa-Vec or pexastimogene devacirepvec) is a **replication-competent oncolytic vaccinia virus** engineered for cancer immunotherapy. Developed initially by Jennerex (later acquired by SillaJen) and Transgene, it features thymidine kinase gene deletion for tumor-selective replication and transgenes encoding GM-CSF (to recruit and activate dendritic cells) and β-galactosidase (as a reporter). The virus selectively replicates in cancer cells, causing direct oncolysis, while inducing systemic antitumor immunity through immunogenic cell death, IFNα secretion, chemokine induction, and T-cell responses. Primarily investigated for **advanced hepatocellular carcinoma (HCC)** as first-line therapy, with activity also in metastatic colorectal cancer liver metastases (CRLM), metastatic melanoma, renal, breast, and soft tissue sarcoma; administered intravenously or intratumorally, often in neoadjuvant settings or combinations (e.g., sorafenib, nivolumab).[2][3][4][7][13][14]

Brand names

Pexa-Vec

Other names

Pexa-Vec